This dependency concern is one of the primary criticisms of pharmaceutical GLP-1 treatment, and it drives many people to explore alternatives
The combination results in three convergent signals: reduced caloric intake (GLP-1/GIP appetite suppression), improved insulin sensitivity (GIP/GLP-1 pancreatic effects), and elevated calorie burn (glucagon thermogenesis)
Step 3: Insurance Navigation Ros concierge team handles prior authorization and paperwork
Side effects are common: about 43% of people felt nauseous, 33% had diarrhea, and about 1 in 5 experienced tingling or burning skin sensations (called dysesthesia) at the highest dose
(2024, September) Retatrutide is a novel triple-agonist targeting GLP-1, GIP, and glucagon receptors, showing in phase 2 trials that it can deliver remarkably large weight losses (up to ~24% over 48 weeks in people with obesity) along with strong improvements in HbA1c, lipid profiles, liver fat (in NAFLD), insulin sensitivity, and other cardiometabolic markers
Positive Reviews Across Trustpilot and third-party review sites the most consistent feedback covers four areas: Onboarding speed with many reviewers noting the questionnaire was straightforward and approval came through faster than expected Delivery with two-day turnaround and discreet packaging highlighted repeatedly especially by patients who valued privacy Portal support with reviewers frequently mentioning responsive and helpful replies from the care team Value for money particularly from patients who previously paid for branded Ozempic or Mounjaro and found the compounded alternative equally effective at a fraction of the price One Trustpilot reviewer described the whole experience as simple and straightforward and said they would have had to jump through so many hoops to get the same medication through traditional channels
